Today Stories

PfizerForAll makes managing everyday health quicker and more convenient for millions of Americans Platform is designed for patients with migraine, COVID-19 or flu, and adults seeking vaccines for preventable diseases, including COVID-19, flu, RSV and pneumococcal pneumonia End-to-end offering gives people an easier way to connect with a qualified healthcare professional the same day, find and book vaccines, receive tests and medications at home or via a preferred pharmacy, and find savings and support if prescribed a Pfizer medicine PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today introduced PfizerForAll , a us…

UCB to divest its mature neurology and allergy business in China, including Keppra®, Vimpat®, Neupro®, Zyrtec®, Xyzal® and the Zhuhai manufacturing site to CBC Group and Mubadala Investment Company for an amount of US$680 million  Strategy in China evolving towards a stronger focus on innovation and partnerships Brussels (Belgium), August 26, 2024 – 07:00 (CEST) – UCB, a global biopharmaceutical company, today announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. This transaction involves the sale, divestment and license of UCB’s mature business (neurology and allergy) in China, including Keppra®, Vimpat®, Neupro®, Zyrtec®, Xyzal®, and the Zhuhai manufacturing site,…

PORTAGE, Mich. – Aug. 22, 2024 – Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire Vertos Medical Inc., a privately held company providing a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis.  Lumbar spinal stenosis affects millions of people globally and is a leading cause of pain and disability. Patients today are seeking minimally invasive treatment options, valuing reduced recovery times and quicker returns to daily life. Vertos Medical’s mild® procedure provides a solution for pain relief and may improve mobility1,2 without the need for major surgery.  “We are committed to helping customers restore patients’ quality of life with interventional solutions to address c…

Greg Friberg, M.D., Appointed EVP, Chief Research & Development Officer as Hank Fuchs, M.D., Will Retire After 15 Years at Company James Sabry, M.D., Ph.D., Appointed EVP, Chief Business Officer SAN RAFAEL, Calif., Aug. 21, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the appointments of Greg Friberg, M.D., as Executive Vice President, Chief Research & Development Officer, succeeding Hank Fuchs, M.D., and James Sabry, M.D., Ph.D., as Executive Vice President, Chief Business Officer. Dr. Friberg, who will join BioMarin effective Sept. 30, is a proven leader with nearly two decades of industry experience. He comes to BioMarin from Amgen, Inc., where he most recently served as Vice President, Global Medical Affairs, Rare Disease. Dr. Friberg bring…

BILLINGHAM, U.K., 1701HRS August 20, 2024:– FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, today hosted a celebration for the opening of its microbial fermentation manufacturing facility in Billingham. This new facility triples existing microbial production throughput with the addition of a new production line equipped with 2 X 4000 L fermenters, primary separations suite and a modular purification suite with an investment over 100 million GBP. To support further expansion, the facility is built with the flexibility to accommodate new projects to meet the emerging needs of FUJIFILM Diosynth Biotechnologies’ partners, and to provide supply chain resilience. This…

AI Nose now has a 79% accuracy in identifying 761 samples across 22 VOCs in Japanese semiconductor manufacturing factories AI Nose can be integrated into robotics systems in smart factories, serving as the digital nose of AI technology SAN DIEGO, CA / ACCESSWIRE / August 19, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA low-dose interferon therapeutics, today announced that its AI Nose has made a significant breakthrough in factory automation with 79% accuracy in detecting 761 samples across 22 different volatile organic compounds (VOCs). This is a remarkable technological advancement in industrial manufacturing safety and smart manufacturing. During its o…

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Advanced eClinical Training (ACT) is proud to announce its top ranking on Forbes Education's prestigious Best CMA Certification Online list for 2024. This recognition is a testament to the institution's unwavering commitment to providing superior education and training for future healthcare professionals. Forbes Education's annual ranking evaluates online Certified Medical Assistant (CMA) programs based on a comprehensive set of criteria including program quality, faculty expertise, student outcomes, and overall value. Advanced eClinical Training has been recognized for its exceptional dedication to excellence in these areas, setting a benchmark for online healthcare education. Key Reasons for Selection: 1. Comprehensive Curriculum:Advanced eCl…

Recognitions, including gold award for Thermo Scientific Orbitrap Astral Mass Spectrometer, underscore importance and role of investing in innovation to address some of the world’s greatest health challenges WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc., the world leader in serving science, has received three R&D 100 Awards for innovations that aid researchers’ and scientists’ work in a variety of life science applications, including proteomics, bioproduction and small-molecule analysis. Notably, the Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer (MS) won gold in the Market Disruptor special recognition category as one of the most significant advancements in mass spectrometry in 15 years. This first-of-its-kind instrument, also recognized in the Analytical/Tes…

Establishes Vantive as a leading standalone kidney care business backed by Carlyle’s global investment team and resources Sale follows robust process focused on maximizing stockholder value Provides increased flexibility to deploy capital toward opportunities to accelerate Baxter’s and Vantive’s respective growth objectives Represents key milestone in Baxter’s ongoing business transformation, enabling heightened strategic clarity, operational efficiency and innovation Baxter shares preliminary outlook for select financial metrics following completion of pending Kidney Care divestiture DEERFIELD, Ill. and NEW YORK, N.Y. - 2024-08-13 Baxter International Inc. (NYSE:BAX), a global medtech leader, and funds managed by global investment firm Carlyle (NASDAQ:CG) today announce…

Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions. The acquisition will strengthen Stryker’s growing healthcare IT offering and wirelessly connected medical device portfolio. This growing segment is of increasing importance as Stryker’s customers continue to face nursing shortages, employee retention challenges, overworked and cognitively burdened staff, and a rise in workplace safety concerns. care.ai adds complementary technology that will integrate seamlessly with the Vocera platform and Stryker’s devices, providing customers with an enterprise-wide ecosystem that can delive…

Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research Hamburg, Germany, 08 August 2024:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research. Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases where there remains a significant unmet medical need for therapies that slow down or reverse disease progression.…

Unique partnership with Medtronic will enable continuous glucose monitoring (CGM) sensors based on Abbott's FreeStyle Libre sensing technology to integrate with Medtronic's insulin delivery systems Abbott now has partnerships with four of the largest companies that develop automated insulin delivery systems – offering more choices to people around the world to benefit from connectivity with Libre technology ABBOTT PARK, Ill., Aug. 7, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading1 FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems. The in…

Partnership Expands Reach of C2N’s Precivity™ Blood Tests in Over 75 Countries to Transform Alzheimer’s Disease Early Diagnosis and Research Agreement Plans to Facilitate a Technology Transfer of C2N’s Proprietary Portfolio of Alzheimer’s Blood Biomarkers to Deliver a Unilabs Testing Network Across Europe LOUIS, MO. and GENEVA, SWITZERLAND — August 7, 2024   Unilabs (“Unilabs”), a leading international provider of diagnostic services, and C2N Diagnostics, LLC (“C2N”),  a pioneer in advanced diagnostic solutions in the field of Alzheimer’s disease (AD) and related neurological disorders, today announced a major milestone in brain health diagnostics and research across Europe and beyond. Unilabs and C2N have signed a multi-year partnership agreement that will increase access to C2N’s Pr…

EQS-News: QUANTRO Therapeutics GmbH / Key word(s): MiscellaneousQUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform06.08.2024 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement. QUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform Austrian Research Promotion Agency FFG awards funding to QUANTRO, accelerating the next development phase of its transcriptomic discovery platform Vienna (Austria), 06 August 2024: QUANTRO Therapeutics GmbH, a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company received an 18-month research grant awarded by the Austrian Research Promot…

Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth PITTSBURGH, July 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has closed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor, bringing to substantial completion all previously announced divestitures. In October, the Company announced it had entered into agreements to divest substantially all of its OTC business, as well as its Women's Healthcare business, its Active Pharmaceutical Ingredients (API) business in India and commercialization rights in certain non-core marke…

Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia Cerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decade AbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $2.92-$2.96 NORTH CHICAGO, Ill., Aug. 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE). With the completion of…

BURLINGTON, N.C., and FREMONT, Calif., July 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Ultima Genomics to utilize its UG 100TM sequencing solution and ppmSeqTM technology to explore new whole genome sequencing (WGS) clinical applications, including molecular residual disease (MRD) in patients with early-stage solid tumor cancers. Labcorp recently introduced Labcorp® Plasma Detect™, the first clinically validated, tumor-informed, WGS-based circulating tumor DNA (ctDNA) MRD solution for research and investigational use. Labcorp intends to use Ultima's UG 100 platform and ppmSeq technology, which, combined with Plasma Detect, have demonstrated in preliminary data the ability t…

Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline as the company is adding an innovative preclinical program with the acquisition of Nerio Therapeutics Inc. (“Nerio”) for a total of up to USD 1.3 billion. Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio to achieve its aim of improving cancer patient outcomes. Nerio’s small molecules inhibit the protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which act as immune checkpoints. Through this mechanism, PTPN1/2 inhibition can activate the immune system to fight cancer cells.  Immune checkpoint blockade with current checkpoint inhibitors has transformed the cancer treatment landscape. However, while this approach works for so…

The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances. LumiraDx’s transformative Point of Care solution will complement Roche’s diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease areas. By integrating LumiraDx, Roche will further its ambition to deliver decentralised solutions that expand global access to testing in primary care settings worldwide. Basel, 29 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the completion of the acquisition of LumiraDx’s Point of Care technology, following the receipt of all required antitrust and regulatory clearances. Roche will now embark on the full integration of the company’s innovative multi-assay point of c…

A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9) after up to four years of follow-up, providing sustained bleed protection and potentially avoiding years of treatment burden with prophylaxis for many patients. NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX® (fidanacogene elaparvovec), a gene therapy for the treatment of severe and moderately severe hemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74. DURVEQTIX is designed to enable people l…